Venus Medtech (Hangzhou) Inc. (2500.HK) Stock

About Venus Medtech (Hangzhou) Inc.

Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company's offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Venus-Vitae, a balloon-expandable dry-tissue product; Venus-PowerX, a self-expanding dry-tissue product; Cardiovalve, a transcatheter valve replacement system for the treatment of patients with mitral regurgitation and in pivotal clinical trial for the treatment of patients with tricuspid regurgitation; and renal artery denervation ablation system for the treatment of hypertension. In addition, the company offers procedural accessories comprising catheter sheath product and balloon catheter. Venus Medtech (Hangzhou) Inc. was incorporated in 2009 and is headquartered in Hangzhou, the People's Republic of China.

Venus Medtech (Hangzhou) Inc. (2500.HK) stock trades at $1.08 with a market capitalization of $474.09M. The stock is valued at a price-to-earnings (P/E) ratio of 16.80, price-to-book of 0.23, price-to-sales of 1.55. Over the past 52 weeks the stock has ranged between $1.01 and $5.47, and currently trades 80.3% below its 52-week high.

On profitability, Venus Medtech (Hangzhou) Inc. generates a return on equity (ROE) of -20.52%, an operating margin of -174.00%, a net profit margin of -132.89%.

Official website: www.venusmedtech.com